Daniel Virnich - 21 May 2026 Form 4 Insider Report for Oncology Institute, Inc. (TOI)

Reporting relationship: Chief Executive Officer
Issuer ticker: TOI
Reported as of: 21 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 May 2026, 17:37:58 UTC
Prior SEC filing: 01 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Mark Hueppelsheuser, Attorney-in-Fact for Daniel Virnich

Key filing fact

Daniel Virnich filed Form 4 for Oncology Institute, Inc. (TOI) on 22 May 2026.

Key facts

This page summarizes Daniel Virnich's Form 4 filing for Oncology Institute, Inc. (TOI).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 22 May 2026, 17:37.

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

CIK 0001891107 Primary reporting owner

Relationship: Chief Executive Officer
Address: C/O THE ONCOLOGY INSTITUTE INC., 18000 STUDEBAKER RD, SUITE 800, CERRITOS
Signature: /s/ Mark Hueppelsheuser, Attorney-in-Fact for Daniel Virnich
Signature date: 22 May 2026

Shares, units, or other non-derivative securities reported in this filing.

TOI transaction

Other

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Explanation of responses 1 footnote

Footnote F1

The Issuer executed the sale to cover the tax liabilities arising from the vesting of an RSU award made on May 21, 2024.